HRSA discloses manufacturers approved for revised 340B rebate pilot
The revised pilot requires providers to verify eligibility through Beacon before manufacturers issue rebates, and drugmakers say it will curb fraud and duplicate discounts.
5 Articles
5 Articles
AbbVie joins US government pilot to test drug discount rebates
Oct 2 (Reuters) – US drugmaker AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines. Here are some details: • The pilot will begin on January 1, 2027, under the government’s 340B program, which helps hospitals and clinics serving low-income patients buy medicines at a discount. • Under the new model, eligible healthcare providers will submit claims through…
HRSA discloses manufacturers approved for revised 340B rebate pilot
Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump administration’s first attempt at kickstarting a rebate pilot.
HRSA approves 10 drug companies for participation in the 340B Rebate Model Pilot Program
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the 340B Rebate Model Pilot Program. The approved companies are AbbVie, Amgen, Astellas Pharma US, AstraZeneca, Bristol Meyers Squibb, Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer and Teva Pharmaceuticals. See the HRSA webpage for more details about the dr…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
